Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 17;19(11):18881-96.
doi: 10.3390/molecules191118881.

Profiling the metabolism of astragaloside IV by ultra performance liquid chromatography coupled with quadrupole/time-of-flight mass spectrometry

Xu-Dong Cheng  1 , Ming-Gang Wei  2
Affiliations

Profiling the metabolism of astragaloside IV by ultra performance liquid chromatography coupled with quadrupole/time-of-flight mass spectrometry

Xu-Dong Cheng et al. Molecules. .

Abstract

Astragaloside IV is a compound isolated from the Traditional Chinese Medicine Astragalus membranaceus, that has been reported to have bioactivities against cardiovascular disease and kidney disease. There is limited information on the metabolism of astragaloside IV, which impedes comprehension of its biological actions and pharmacology. In the present study, an ultra-performance liquid chromatography coupled with quadrupole/time-of-flight mass spectrometry (UPLC-Q-TOF-MS/MS)-based approach was developed to profile the metabolites of astragaloside IV in rat plasma, bile, urine and feces samples. Twenty-two major metabolites were detected. The major components found in plasma, bile, urine and feces included the parent chemical and phases I and II metabolites. The major metabolic reactions of astragaloside IV were hydrolysis, glucuronidation, sulfation and dehydrogenation. These results will help to improve understanding the metabolism and reveal the biotransformation profiling of astragaloside IV in vivo. The metabolic information obtained from our study will guide studies into the pharmacological activity and clinical safety of astragaloside IV.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The XICs (A), MS (B) and MS/MS (C) spectra of astragaloside IV.
Figure 2
Figure 2
Representative TIC chromatograms of rat samples after intragastric administration of astragaloside IV at 80 mg/kg. (A) plasma; (B) bile; (C) urine; (D) feces.
Figure 3
Figure 3
Mass spectra (MS/MS) of the metabolites of astragaloside IV.
Figure 3
Figure 3
Mass spectra (MS/MS) of the metabolites of astragaloside IV.
Figure 4
Figure 4
Proposed major metabolic pathway of astragaloside IV.
See this image and copyright information in PMC

References

    1. Bu W., Akama T., Chanda S., Sullivan D., Ciaravino V., Jarnagin K., Freund Y., Sanders V., Chen C.W., Fan X., et al. Early rapid identification of in vivo rat metabolites of AN6414, a novel boron-containing PDE4 inhibitor by QTRAP LC/MS/MS to support drug discovery. J. Pharm. Biomed. Anal. 2012;70:344–353. doi: 10.1016/j.jpba.2012.05.024. - DOI - PubMed
    1. Kumar V., Schuck E.L., Pelletier R.D., Farah N., Condon K.B., Ye M., Rowbottom C., King B.M., Zhang Z.Y., Saxton P.L., et al. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. Cancer Chemother. Pharm. 2012;69:229–237. doi: 10.1007/s00280-011-1687-8. - DOI - PubMed
    1. Hong Z., Zhao L., Wang X., Le J., Jia J., Chai Y., Zhang G. High-performance liquid chromatography-time-of-flight mass spectrometry with adjustment of fragmentor voltages for rapid identification of alkaloids in rat plasma after oral administration of rhizoma Corydalis extracts. J. Sep. Sci. 2012;35:1690–1696. doi: 10.1002/jssc.201200126. - DOI - PubMed
    1. Zhao Y.Y., Su Q., Cheng X.L., Tan X.J., Bai X., Lin R.C. Pharmacokinetics, bioavailability and metabolism of rhaponticin in rat plasma by UHPLC-Q-TOF/MS and UHPLC DaD-MSn. Bioanalysis. 2012;4:713–723. doi: 10.4155/bio.12.24. - DOI - PubMed
    1. Editorial Committee of Chinese Pharmacopeia . Pharmacopeia of the People’s Republic of China, Sec. A. Chemical Industry Press, Inc.; Beijing, China: 2010. pp. 283–284.

Publication types

LinkOut - more resources